Uptake of genital mucosal sampling in HVTN 097, a Phase 1b HIV vaccine trial in South Africa

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Lazarus, Erica Maxine ^a   Otwombe, Kennedy ^a   Adonis, Tania ^b   Sebastian, Elaine ^c   Gray, Glenda ^a   Grunenberg, Nicole ^d   Roux, Surita ^c   Churchyard, Gavin ^b   Innes, Craig ^b   Laher, Fatima ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b AURUM INSTITUTE   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO;

ADULT; AGE; ARTICLE; BODILY SECRETIONS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INFORMED CONSENT; MALE; MUCOSAL SAMPLING; PHASE 1 CLINICAL TRIAL; RECTUM MUCOSA; SAMPLING; SOUTH AFRICA; UTERINE CERVIX MUCOSA; VACCINATION; ADOLESCENT; CLINICAL TRIAL; EPIDEMIOLOGY; GENITAL SYSTEM; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; LABORATORY DIAGNOSIS; MIDDLE AGED; MUCOSA; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AIDS VACCINES; FEMALE; GENITALIA; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUCOUS MEMBRANE; RISK FACTORS; SOUTH AFRICA; SPECIMEN HANDLING; YOUNG ADULT;

EID: 84913573627     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112303     Document Type: Article

References (27)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS) (2014) The Gap Report. Available: http://www.unaids.org/en/resources/documents/2014/Accessed 2014 September 5.
2. Stover J, Bollinger L, Hecht R, Williams C, Roca E (2007) The impact of an AIDS vaccine in developing countries: A new model and initial results. Health Aff (Millwood) 26: 1147-1158
3. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220
4. Iqbal SM, Kaul R (2008) Mucosal innate immunity as a determinant of HIV susceptibility. Am J Reprod Immunol 59: 44-54
5. Mazzoli S, Trabattoni D, Lo Caputo S, Piconi S, Ble C, et al. (1997) HIVspecific mucosal and cellular immunity in HIV-seronegative partners of HIVseropositive individuals. Nat Med 3: 1250-1257
6. Wright PF, Mestecky J, McElrath MJ, Keefer MC, Gorse GJ, et al. (2004) Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein. J Infect Dis 189: 1221-1231
7. Yang OO, Ibarrondo FJ, Price C, Hultin LE, Elliott J, et al. (2014) Differential Blood and Mucosal Immune Responses against an HIV-1 Vaccine Administered via Inguinal or Deltoid Injection. PLoS One 9: e88621
8. Mattapallil JJ, Hill B, Douek DC, Roederer M (2006) Systemic vaccination prevents the total destruction of mucosal CD4 T cells during acute SIV challenge. J Med Primatol 35: 217-224
9. Baig J, Levy DB, McKay PF, Schmitz JE, Santra S, et al. (2002) Elicitation of simian immunodeficiency virus-specific cytotoxic T lymphocytes in mucosal compartments of rhesus monkeys by systemic vaccination. J Virol 76: 11484-11490
10. United States Army Medical Research and Materiel Command (2014) RV306: Study of Boosting Strategies After Vaccination With ALVAC-HIV and AIDSVAX B/E. Available: http://clinicaltrials.gov/ct2/show/NCT01931358?term=RV+306&rank=2. Accessed 2014 September 3.
11. HIV Vaccine Trials Network Mucosal Immunology Group. http://public. hivmucosalgroup.org/Pages/default.aspx. Accessed 2014 September 4
12. Mehra V, Musib R, Schito ML (2010) Towards developing standardized protocols for evaluation of cellular mucosal immune responses - Recommendations from a DAIDS/NIH workshop, June 15-16, 2009. Vaccine 28: 4689-4694
13. Ruzagira E, Wandiembe S, Bufumbo L, Levin J, Price MA, et al. (2009) Willingness to participate in preventive HIV vaccine trials in a community-based cohort in south western Uganda. Trop Med Int Health 14: 196-203
14. Smit J, Middelkoop K, Myer L, Seedat S, Bekker LG, et al. (2006) Willingness to participate in HIV vaccine research in a peri-urban South African community. Int J STD AIDS 17: 176-179
15. Otwombe KN, Sikkema KJ, Dietrich J, de Bruyn G, van der Watt M, et al. (2011) Willingness to participate in biomedical HIV prevention studies after the HVTN 503/Phambili trial: A survey conducted among adolescents in Soweto, South Africa. J Acquir Immune Defic Syndr 58: 211-218
16. Middelkoop K, Myer L, Mark D, Mthimunye SP, Smit J, et al. (2008) Adolescent and adult participation in an HIV vaccine trial preparedness cohort in South Africa. J Adolesc Health 43: 8-14
17. Fincham D, Kagee A, Swartz L (2010) Inhibitors and facilitators of willingness to participate (WTP) in an HIV vaccine trial: construction and initial validation of the Inhibitors and Facilitators of Willingness to Participate Scale (WPS) among women at risk for HIV infection. AIDS Care 22: 452-461
18. Dhalla S, Poole G (2011) Motivators of enrolment in HIV vaccine trials: A review of HIV vaccine preparedness studies. AIDS Care 23: 1430-1447
19. Shisana O, Rehle T, Simbayi L, Zuma K, Jooste S, et al. (2014) South African National HIV Prevalence, Incidence and Behaviour Survey, 2012. Cape Town
20. de Bruyn G, Skhosana N, Robertson G, McIntyre JA, Gray GE (2008) Knowledge and attitudes towards HIV vaccines among Soweto adolescents. BMC Res Notes 1: 76
21. Buchbinder SP, Metch B, Holte SE, Scheer S, Coletti A, et al. (2004) Determinants of enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation. J Acquir Immune Defic Syndr 36: 604-612
22. World Health Organization (2001) Guidelines for the Management of Sexually Transmitted Infections. Available: http://apps.who.int/medicinedocs/en/d/ Jh2942e/Accessed 2014 September 1
23. Lewis D, Marumo E (2009) Revision of the national guideline for first-line comprehensive management and control of sexually transmitted infections: what's new and why? South African Journal of Epidemiology and Infection 24: 6-9
24. South African National Department of Health (2000) National Guideline for Cervical Cancer Screening Programme. Available: http://www.kznhealth.gov. za/cervicalcancer.pdf Accessed 2014 January 14
25. Lakhani A, Gandhi K, Collumbien M (2001) Addressing semen loss concerns: Towards culturally appropriate HIV/AIDS interventions in Gujarat, India. Reprod Health Matters 9: 49-59
26. Meston CM, Trapnell PD, Gorzalka BB (1996) Ethnic and gender differences in sexuality: variations in sexual behavior between Asian and non-Asian university students. Arch Sex Behav 25: 33-72
27. Dewaraja R, Sasaki Y (1991) Semen-loss syndrome: A comparison between Sri Lanka and Japan. Am J Psychother 45: 14-20.